Lipoprotein(a) distribution and its association with carotid arteriopathy in the Chinese population

Lin, Lijin; Deng, Ke‐Qiong; Chen, Ze; Lei, Fang; Qin, Jianghui; Huang, Xuewei; Sun, Tao; Zhang, Xingyuan; Hu, Yingying; Zhang, Peng; Ji, Yan‐Xiao; Zhang, Xiaojing; She, Zhi‐Gang; Lu, Zhibing; Cai, Jingjing; Li, Hongliang

doi:10.1016/j.atherosclerosis.2023.03.007

Cited by 8 publications

(4 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Table 1 represented the characteristics of all included studies. Among all included 41 studies, 30 were published in Chinese ( 47 – 60 , 63 , 64 , 68 – 70 , 73 – 79 , 81 , 85 – 87 ), and 11 were in English ( 61 , 62 , 65 – 67 , 71 , 72 , 80 , 82 – 84 ). All studies were published between 2012 and 2023.…”

Section: Resultsmentioning

confidence: 99%

“…All studies were published between 2012 and 2023. As for study area, 14 studies ( 47 , 49 , 50 , 58 , 61 , 63 , 69 , 70 , 72 , 75 – 77 , 83 , 85 ) were conducted on the populations of northern China, while 17 studies ( 48 , 51 – 57 , 59 , 68 , 71 , 73 , 74 , 78 , 84 , 86 , 87 ) focused on southern counterparts, and 10 nationwide studies ( 60 , 62 , 64 – 67 , 79 – 81 , 82 ) were conducted.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence, awareness, treatment, and control of dyslipidemia in Chinese adults: a systematic review and meta-analysis

Xia

Chen

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundResearchers have conducted a considerable number of epidemiological studies on dyslipidemia in China over recent years. Nevertheless, a representative study to comprehensively appraise for the epidemiological status of dyslipidemia is still lacked. This meta-analysis is intended to explore the pooled prevalence, rates of awareness, treatment, and control of dyslipidemia among adults in Chinese Mainland.Materials and methodsA systematic review was performed on relevant cross-sectional studies published since January 2012 by searching six authoritative literature databases. Meta-analyses were conducted in included studies based on a random-effect model to summarize the epidemiological status of dyslipidemia in China. A potential source of heterogeneity was detected by subgroup analysis and meta-regression. Publication bias was assessed by Egger's test and funnel plots. A sensitivity analysis was conducted to examine the study quality's influence on the pooled estimate of prevalence and rates of awareness, treatment, and control.ResultsForty-one original researches with a total of 1,310,402 Chinese participants were finally included in the meta-analysis. The prevalence, rates of awareness, treatment, and control of dyslipidemia were 42.1%, 18.2%, 11.6%, and 5.4%, respectively. With a pooled prevalence estimate at 24.5%, low HDL-C was the most prevalent among various dyslipidemia types, followed by hypertriglyceridemia (TG) (15.4%), hypercholesterolemia (TC) (8.3%), and high LDL-C (7.1%). The pooled prevalence of elevated serum lipoprotein(a) [Lp(a)] was 19.4%. By gender, the prevalence of dyslipidemia was 47.3% in males and 38.8% in females. Subgroup analyses revealed that the prevalence in southern and urban areas were higher than their counterparts. Females and population in urban areas tended to possess higher rates of awareness, treatment, and control. Meta-regression analyses suggested that the year of screening influenced prevalence estimates for dyslipidemia. The impact of the study's quality on the pooled estimates is insignificant.ConclusionOur study suggested a severe epidemic situation of dyslipidemia among adults in Chinese Mainland. More importantly, the awareness, treatment, and control rates were extremely low, revealing that dyslipidemia is a grave health issue. Consequently, we should attach more importance to the management of dyslipidemia, especially in economically underdeveloped areas.Systematic review registrationPROSPERO [CRD42022366456].

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Prevalence, awareness, treatment, and control of dyslipidemia in Chinese adults: a systematic review and meta-analysis

Xia

Chen

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…They found that Lp(a) levels exceeding 30 mg/dL were significantly associated with carotid plaque formation, although CIMT was not influenced by serum Lp(a) concentrations [ 120 ]. Conversely, a large population cross-sectional study involving 411,634 healthy Chinese individuals reported that Lp(a) concentrations ≥50 mg/dL were associated with a higher prevalence of carotid atherosclerosis, as determined using CIMT measurements and an assessment of carotid plaques [ 121 ].…”

Section: The Role Of Lp(a) In Cardiovascular Disease: Focusing On Ath...mentioning

confidence: 99%

Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Where Do We Stand?

Tsioulos,

Kounatidis,

Vallianou

et al. 2024

IJMS

View full text Add to dashboard Cite

Lipoprotein(a) [Lp(a)] consists of a low-density lipoprotein-like molecule and an apolipoprotein(a) [apo(a)] particle. Lp(a) has been suggested to be an independent risk factor of atherosclerotic cardiovascular disease (ASCVD). Lp(a) plasma levels are considered to be 70–90% genetically determined through the codominant expression of the LPA gene. Therefore, Lp(a) levels are almost stable during an individual’s lifetime. This lifelong stability, together with the difficulties in measuring Lp(a) levels in a standardized manner, may account for the scarcity of available drugs targeting Lp(a). In this review, we synopsize the latest data regarding the structure, metabolism, and factors affecting circulating levels of Lp(a), as well as the laboratory determination measurement of Lp(a), its role in the pathogenesis of ASCVD and thrombosis, and the potential use of various therapeutic agents targeting Lp(a). In particular, we discuss novel agents, such as antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) that are currently being developed and target Lp(a). The promising role of muvalaplin, an oral inhibitor of Lp(a) formation, is then further analyzed.

show abstract

“…Lipoprotein(a) Lp(a) was evaluated in a Chinese cross-sectional study that included 75305 adults with Lp(a) measurements that underwent carotid ultrasound [ 11 ]. A multiple logistic regression analysis showed that participants with Lp(a) levels ≥ 50 mg/dL had an increased risk of carotid intima-media thickness (cIMT) ≥ 1.0 mm (OR = 1.138, 95% CI, 1.071–1.208) and carotid plaque (OR = 1.296, 95% CI, 1.219–1.377) compared with those with Lp(a) levels < 50 mg/dL [ 11 ].…”

Section: Biomarkers Associated With Laa Strokementioning

confidence: 99%

Update on Biomarkers Associated with Large-Artery Atherosclerosis Stroke

Rosário

Fonseca

2023

Biomolecules

View full text Add to dashboard Cite

Intracranial and extracranial large-artery atherosclerosis (LAA) are a main cause of ischemic stroke. Biomarkers may aid in the diagnosis of LAA and help to stratify patients’ risk of stroke. We performed a narrative review of the literature, mainly published in the last five years, with the aim of identifying biomarkers associated either with intracranial or extracranial LAA in humans. Several potential biomarkers of LAA, mainly related to lipidic pathways and inflammation, have been studied. Diagnostic biomarkers of LAA were evaluated by measuring biomarkers levels in patients with LAA stroke and other stroke etiologies. Some biomarkers were associated with the functional prognosis of LAA stroke patients. Increased levels of IL-6 and sLOX-1 were associated with a risk of progression of carotid atherosclerotic disease. Findings support the notion that the immune system plays a central role in the pathogenesis of LAA. Overall, in most studies, results were not externally validated. In the future, biomarkers could be useful for the selection of patients for clinical trials. To adopt these biomarkers in clinical practice, we will need robust multicentric studies proving their reproducibility and a clear practical applicability for their use.

show abstract

Lipoprotein(a) distribution and its association with carotid arteriopathy in the Chinese population

Cited by 8 publications

References 53 publications

Prevalence, awareness, treatment, and control of dyslipidemia in Chinese adults: a systematic review and meta-analysis

Prevalence, awareness, treatment, and control of dyslipidemia in Chinese adults: a systematic review and meta-analysis

Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Where Do We Stand?

Update on Biomarkers Associated with Large-Artery Atherosclerosis Stroke

Contact Info

Product

Resources

About